Lack of Diligence. In the event that CFFT fails to exercise its good faith efforts to develop and commercialize a Collaboration Product within [...***...] years after the Completion Date, the rights to the Structure Data, Early Lead Series and Lead Series granted to CFFT pursuant to Section 4.1 shall revert to SGX and SGX thereafter shall have the right to develop, manufacture, make, have made, import, use, distribute, offer for sale and sell Collaboration Products. In the event of such reversion, SGX shall pay to 15 ***CONFIDENTIAL TREATMENT REQUESTED CFFT [...***...] percent ([...***...]%) of any amount SGX receives from the sale of any Collaboration Product.
Appears in 3 contracts
Sources: Drug Discovery Agreement (SGX Pharmaceuticals, Inc.), Drug Discovery Agreement (SGX Pharmaceuticals, Inc.), Drug Discovery Agreement (SGX Pharmaceuticals, Inc.)